Sources tell CNBCTV18 that the revenue share from COVID-19 testing for diagnostic companies has risen to 27-30% in the month of March vs a 15% share in January
#THYROCARE #Dr Lal PathLabs
#THYROCARE #Dr Lal PathLabs
#Thyrocare Large Trade | 29.11 lakh shares (5.51% equity) worth ₹142.14 crore change hands at average of ₹488/share